SPRO Annual CFI
$0.00
-$33.81 M-100.00%
31 December 2023
Summary:
As of January 23, 2025, SPRO annual cash flow from investing activities is $0.00, with the most recent change of -$33.81 million (-100.00%) on December 31, 2023. During the last 3 years, it has fallen by -$10.47 million (-100.00%). SPRO annual CFI is now -100.00% below its all-time high of $33.81 million, reached on December 31, 2022.SPRO Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SPRO Quarterly CFI
N/A
30 September 2024
Summary:
SPRO quarterly cash flow from investing activities is not available.SPRO Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SPRO TTM CFI
N/A
30 September 2024
Summary:
SPRO TTM cash flow from investing activities is not available.SPRO TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SPRO Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -100.0% | - | - |
| 3 y3 years | -100.0% | - | - |
| 5 y5 years | +100.0% | - | - |
SPRO Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -100.0% | |||||
| 5 y | 5-year | -100.0% | |||||
| alltime | all time | -100.0% | +100.0% |
Spero Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $0.00(-100.0%) | - | - |
| Dec 2022 | $33.81 M(+340.7%) | $0.00(-100.0%) | $33.81 M(+221.0%) |
| Sept 2022 | - | -$129.00 K(-100.3%) | $10.53 M(-62.0%) |
| June 2022 | - | $50.00 M(-411.3%) | $27.69 M(-343.0%) |
| Mar 2022 | - | -$16.06 M(-31.0%) | -$11.39 M(-248.5%) |
| Dec 2021 | $7.67 M(-26.7%) | -$23.27 M(-236.7%) | $7.67 M(-187.3%) |
| Sept 2021 | - | $17.02 M(+55.9%) | -$8.79 M(-59.8%) |
| June 2021 | - | $10.92 M(+263.6%) | -$21.87 M(+52.9%) |
| Mar 2021 | - | $3.00 M(-107.6%) | -$14.30 M(-236.6%) |
| Dec 2020 | $10.47 M | -$39.74 M(-1106.3%) | $10.47 M(-77.3%) |
| Sept 2020 | - | $3.95 M(-78.6%) | $46.11 M(+75.5%) |
| June 2020 | - | $18.48 M(-33.4%) | $26.27 M(-19.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $27.78 M(-777.6%) | $32.63 M(+10.5%) |
| Dec 2019 | $29.53 M(-135.5%) | -$4.10 M(-74.2%) | $29.53 M(-27.8%) |
| Sept 2019 | - | -$15.89 M(-163.9%) | $40.92 M(-358.7%) |
| June 2019 | - | $24.84 M(+0.7%) | -$15.81 M(-55.7%) |
| Mar 2019 | - | $24.67 M(+238.6%) | -$35.66 M(-57.1%) |
| Dec 2018 | -$83.16 M(>+9900.0%) | $7.29 M(-110.0%) | -$83.16 M(-8.1%) |
| Sept 2018 | - | -$72.62 M(-1552.4%) | -$90.47 M(+406.8%) |
| June 2018 | - | $5.00 M(-121.9%) | -$17.85 M(-21.9%) |
| Mar 2018 | - | -$22.82 M(>+9900.0%) | -$22.85 M(>+9900.0%) |
| Dec 2017 | -$27.00 K(-96.7%) | -$27.00 K(<-9900.0%) | -$27.00 K(<-9900.0%) |
| Sept 2017 | - | $0.00 | $0.00 |
| Dec 2016 | -$830.00 K(+257.8%) | - | - |
| Dec 2015 | -$232.00 K | - | - |
FAQ
- What is Spero Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Spero Therapeutics?
- What is Spero Therapeutics annual CFI year-on-year change?
- What is the all time high quarterly CFI for Spero Therapeutics?
- What is the all time high TTM CFI for Spero Therapeutics?
What is Spero Therapeutics annual cash flow from investing activities?
The current annual CFI of SPRO is $0.00
What is the all time high annual CFI for Spero Therapeutics?
Spero Therapeutics all-time high annual cash flow from investing activities is $33.81 M
What is Spero Therapeutics annual CFI year-on-year change?
Over the past year, SPRO annual cash flow from investing activities has changed by -$33.81 M (-100.00%)
What is the all time high quarterly CFI for Spero Therapeutics?
Spero Therapeutics all-time high quarterly cash flow from investing activities is $50.00 M
What is the all time high TTM CFI for Spero Therapeutics?
Spero Therapeutics all-time high TTM cash flow from investing activities is $46.11 M